Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2016 1
2017 2
2018 1
2019 1
2020 1
2021 5
2022 4
2023 4
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH, Mog BJ, Hou W, Justesen S, Blosser R, Tam A, Anagnostou V, Cottrell TR, Guo H, Chan HY, Singh D, Thapa S, Dykema AG, Burman P, Choudhury B, Aparicio L, Cheung LS, Lanis M, Belcaid Z, El Asmar M, Illei PB, Wang R, Meyers J, Schuebel K, Gupta A, Skaist A, Wheelan S, Naidoo J, Marrone KA, Brock M, Ha J, Bush EL, Park BJ, Bott M, Jones DR, Reuss JE, Velculescu VE, Chaft JE, Kinzler KW, Zhou S, Vogelstein B, Taube JM, Hellmann MD, Brahmer JR, Merghoub T, Forde PM, Yegnasubramanian S, Ji H, Pardoll DM, Smith KN. Caushi JX, et al. Among authors: skaist a. Nature. 2021 Aug;596(7870):126-132. doi: 10.1038/s41586-021-03752-4. Epub 2021 Jul 21. Nature. 2021. PMID: 34290408 Free PMC article.
Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer.
Graham MK, Wang R, Chikarmane R, Abel B, Vaghasia A, Gupta A, Zheng Q, Hicks J, Sysa-Shah P, Pan X, Castagna N, Liu J, Meyers J, Skaist A, Zhang Y, Rubenstein M, Schuebel K, Simons BW, Bieberich CJ, Nelson WG, Lupold SE, DeWeese TL, De Marzo AM, Yegnasubramanian S. Graham MK, et al. Among authors: skaist a. Nat Commun. 2024 Aug 28;15(1):7414. doi: 10.1038/s41467-024-51450-2. Nat Commun. 2024. PMID: 39198404 Free PMC article.
Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer.
Graham MK, Wang R, Chikarmane R, Wodu B, Vaghasia A, Gupta A, Zheng Q, Hicks J, Sysa-Shah P, Pan X, Castagna N, Liu J, Meyers J, Skaist A, Zhang Y, Schuebel K, Simons BW, Bieberich CJ, Nelson WG, Lupold SE, DeWeese TL, De Marzo AM, Yegnasubramanian S. Graham MK, et al. Among authors: skaist a. bioRxiv [Preprint]. 2023 Oct 17:2023.09.07.553268. doi: 10.1101/2023.09.07.553268. bioRxiv. 2023. Update in: Nat Commun. 2024 Aug 28;15(1):7414. doi: 10.1038/s41467-024-51450-2. PMID: 37905029 Free PMC article. Updated. Preprint.
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC.
Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL, Antony L, Yang Y, Gomes-Alexandre C, Hicks JL, Jones T, Bowers KA, Eskra JN, Meyers J, Gupta A, Skaist A, Yegnasubramanian S, Luo J, Brennen WN, Kachhap SK, Antonarakis ES, De Marzo AM, Isaacs JT, Markowski MC, Denmeade SR. Sena LA, et al. Among authors: skaist a. J Clin Invest. 2022 Dec 1;132(23):e162396. doi: 10.1172/JCI162396. J Clin Invest. 2022. PMID: 36194476 Free PMC article.
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH, Mog BJ, Hou W, Justesen S, Blosser R, Tam A, Anagnostou V, Cottrell TR, Guo H, Chan HY, Singh D, Thapa S, Dykema AG, Burman P, Choudhury B, Aparicio L, Cheung LS, Lanis M, Belcaid Z, El Asmar M, Illei PB, Wang R, Meyers J, Schuebel K, Gupta A, Skaist A, Wheelan S, Naidoo J, Marrone KA, Brock M, Ha J, Bush EL, Park BJ, Bott M, Jones DR, Reuss JE, Velculescu VE, Chaft JE, Kinzler KW, Zhou S, Vogelstein B, Taube JM, Hellmann MD, Brahmer JR, Merghoub T, Forde PM, Yegnasubramanian S, Ji H, Pardoll DM, Smith KN. Caushi JX, et al. Among authors: skaist a. Nature. 2021 Oct;598(7881):E1. doi: 10.1038/s41586-021-03893-6. Nature. 2021. PMID: 34608287 Free PMC article. No abstract available.
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
Freeman ZT, Nirschl TR, Hovelson DH, Johnston RJ, Engelhardt JJ, Selby MJ, Kochel CM, Lan RY, Zhai J, Ghasemzadeh A, Gupta A, Skaist AM, Wheelan SJ, Jiang H, Pearson AT, Snyder LA, Korman AJ, Tomlins SA, Yegnasubramanian S, Drake CG. Freeman ZT, et al. Among authors: skaist am. J Clin Invest. 2020 Mar 2;130(3):1405-1416. doi: 10.1172/JCI128672. J Clin Invest. 2020. PMID: 32015231 Free PMC article.
Single-cell atlas of epithelial and stromal cell heterogeneity by lobe and strain in the mouse prostate.
Graham MK, Chikarmane R, Wang R, Vaghasia A, Gupta A, Zheng Q, Wodu B, Pan X, Castagna N, Liu J, Meyers J, Skaist A, Wheelan S, Simons BW, Bieberich C, Nelson WG, DeWeese TL, De Marzo AM, Yegnasubramanian S. Graham MK, et al. Among authors: skaist a. Prostate. 2023 Feb;83(3):286-303. doi: 10.1002/pros.24460. Epub 2022 Nov 13. Prostate. 2023. PMID: 36373171
CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancers.
Teh SSK, Bowland K, Halper-Stromberg E, Kotwal A, Bennett A, Skaist A, Tang J, Cai F, Macoretta A, Liang H, Kamiyama H, Wheelan S, Lin MT, Hruban RH, Hung CF, Goldstein M, Scharpf RB, Roberts NJ, Eshleman JR. Teh SSK, et al. Among authors: skaist a. NAR Cancer. 2024 Jun 19;6(2):zcae028. doi: 10.1093/narcan/zcae028. eCollection 2024 Jun. NAR Cancer. 2024. PMID: 38915758 Free PMC article.
CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancers.
Teh SSK, Bowland K, Bennett A, Halper-Stromberg E, Skaist A, Tang J, Cai F, Macoretta A, Liang H, Kamiyama H, Wheelan S, Lin MT, Hruban RH, Scharpf RB, Roberts NJ, Eshleman JR. Teh SSK, et al. Among authors: skaist a. bioRxiv [Preprint]. 2023 Oct 10:2023.04.15.537042. doi: 10.1101/2023.04.15.537042. bioRxiv. 2023. Update in: NAR Cancer. 2024 Jun 19;6(2):zcae028. doi: 10.1093/narcan/zcae028. PMID: 37131822 Free PMC article. Updated. Preprint.
Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment.
Sidiropoulos DN, Rafie CI, Jang JK, Castanon S, Baugh AG, Gonzalez E, Christmas BJ, Narumi VH, Davis-Marcisak EF, Sharma G, Bigelow E, Vaghasia A, Gupta A, Skaist A, Considine M, Wheelan SJ, Ganesan SK, Yu M, Yegnasubramanian S, Stearns V, Connolly RM, Gaykalova DA, Kagohara LT, Jaffee EM, Fertig EJ, Roussos Torres ET. Sidiropoulos DN, et al. Among authors: skaist a. Cancer Immunol Res. 2022 May 3;10(5):656-669. doi: 10.1158/2326-6066.CIR-21-0170. Cancer Immunol Res. 2022. PMID: 35201318 Free PMC article.
23 results